Navigation Links
2 Independent Studies Released on the Effectiveness of Prostate Cancer Treatment

WESTMONT, Ill., Sept. 1 /PRNewswire/ -- For years, the debate has been ongoing regarding the best treatment method for prostate cancer patients. Now, two independent studies have reached similar conclusions. Already considered a good option for prostate cancer patients, brachytherapy (radiation seed implants) now has the backing of research from the Prostate Cancer Foundation of Chicago and The Taussig Cancer Center at Cleveland Clinic, proving a superior disease-free survival rate for patients with early stage prostate cancer.

In an 11-year study, the Prostate Cancer Foundation of Chicago, a non-profit organization that funds patient support programs, clinical research and public education, analyzed 9,137 patients between 1997 and 2008 who were treated for prostate cancer with brachytherapy at Chicago Prostate Center. 67.5% of the patients were regarded as low risk, 29.36% as intermediate, and 1.01% as high.

Of those patients, overall cure rates were 96%, 84%, and 75% for low, intermediate, and high risk patients, respectively. When combined with external beam radiation therapy in intermediate and high risk patients, the brachytherapy results far exceed those of surgery.

The Taussig Cancer Center at Cleveland Clinic has released their similar 2008 outcomes, demonstrating brachytherapy to be superior to surgery in all cases. For low risk patients, the study found a 95% survival rate after five years, 89% for intermediate risk, and 71% for high risk patients. This research concluded that, for low risk patients, brachytherapy was equally successful as external beam radiation, but more successful than a radical prostatectomy.

In addition to its effectiveness, brachytherapy is a minimally invasive treatment. Patients with prostate cancer in the T1 or T2 stages (meaning the cancer hasn't spread beyond the prostate) choose brachytherapy for a number of reasons:

  • No incisions, minimal pain and blood loss
  • Urinary incontinence rates less than 1% - compared to 10% with surgery
  • 6-25% chance of sexual dysfunction following procedure - compared to 50% with surgery
  • Lower rates of bowel irritation compared to external beam radiation
  • Convenience - one-time, outpatient procedure, patients can return to normal activity within a day
  • Lower cost compared to external beam radiation and surgery

For more information on the Prostate Cancer Foundation of Chicago research, visit For more information on the Taussig Cancer Center at Cleveland Clinic, visit

SOURCE Prostate Cancer Foundation of Chicago
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Are Bargaining Groups Hired by Independent Drugstores Causing Payment Delays to Pharmacies?
2. PCMA Statement on the Independent Drugstore Lobby Agenda
3. Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Managements Internal Control Review Efforts and on Legal Proceedings
4. IRIDEX Appoints Burr, Pilger & Mayer New Independent Auditor
5. Nationwide independent Taser study results suggest devices are safe
6. KV Pharmaceutical Company Reports Results of Special Independent Committee Review of Stock Option Grants
7. Schwab Institutional Introduces Healthcare and Benefits Assistance for Independent Advisor Firms
8. GHI to Provide Independent Personal Health Advocate for Medicare Members
9. PCMA Statement on Independent Pharmacy Antitrust Legislation
10. Chiltern Announces Acquisition of an Independent USA Based Clinical Research Organization, Clinical Trial Management Services, Inc.
11. Medical Services Receives Independent Test Results
Post Your Comments:
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: